<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37783557</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2162-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>171</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>International review of neurobiology</Title><ISOAbbreviation>Int Rev Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Positive and negative cell therapy in randomized control trials for central nervous system diseases.</ArticleTitle><Pagination><StartPage>241</StartPage><EndPage>254</EndPage><MedlinePgn>241-254</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/bs.irn.2023.05.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0074-7742(23)00045-4</ELocationID><Abstract><AbstractText>Neurorestorative cell therapies have been tested to treat patients with nervous system diseases for over 20 years. Now it is still hard to answer which kinds of cells can really play a role on improving these patients' quality of life. Non-randomized clinical trials or studies could not provide strong evidences in answering this critical question. In this review, we summarized randomized clinical trials of cell therapies for central nervous diseases, such as stroke, spinal cord injury, cerebral palsy (CP), Parkinson's disease (PD), multiple sclerosis (MS), brain trauma, amyotrophic lateral sclerosis (ALS), etc. Most kinds of cell therapies demonstrated negative results for stoke, brain trauma and amyotrophic lateral sclerosis. A few kinds of cell therapies showed neurorestorative effects in this level of evidence-based medicine, such as olfactory ensheating cells for chronic ischemic stroke. Some kinds of cells showed positive or negative effects from different teams in the same or different diseases. We analyzed the possible failed reasons of negative results and the cellular bio-propriety basis of positive results. Based on therapeutic results of randomized control trials and reasonable analysis, we recommend: (1) to further conduct trials for successful cell therapies with positive results to increase neurorestorative effects; (2) to avoid in repeating failed cell therapies with negative results in same diseases because it is nonsense for them to be done with similar treatment methods, such as cell dosage, transplanting way, time of window, etc. Furthermore, we strongly suggest not to do non-randomized clinical trials for cells that had shown negative results in randomized clinical trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Di</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Beijing Hongtianji Neuroscience Academy, Beijing, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Hongyun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Beijing Hongtianji Neuroscience Academy, Beijing, P.R. China. Electronic address: huanghongyun001@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saberi</LastName><ForeName>Hooshang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Hari Shanker</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>International Experimental Central Nervous System Injury &amp; Repair (IECNSIR), Dept. of Surgical Sciences, Anesthesiology &amp; Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int Rev Neurobiol</MedlineTA><NlmUniqueID>0374740</NlmUniqueID><ISSNLinking>0074-7742</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002493" MajorTopicYN="Y">Central Nervous System Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064987" MajorTopicYN="N">Cell- and Tissue-Based Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001925" MajorTopicYN="N">Brain Damage, Chronic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cerebral palsy</Keyword><Keyword MajorTopicYN="N">Multiple sclerosis The strong suggestions</Keyword><Keyword MajorTopicYN="N">Neurorestorative cell therapies</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Randomized control trials</Keyword><Keyword MajorTopicYN="N">Spinal cord injury</Keyword><Keyword MajorTopicYN="N">Stroke</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>20</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37783557</ArticleId><ArticleId IdType="doi">10.1016/bs.irn.2023.05.017</ArticleId><ArticleId IdType="pii">S0074-7742(23)00045-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>